Sarah Whelan, PhD
Science Writer
at Technology Networks
Sarah joined Technology Networks in 2022 after completing a PhD in cancer biology, where her research focused on the development of colon cancers. In her role as science writer and editor, Sarah covers scientific news and a range of other content types, leading the site's coverage of drug discovery, biopharma and cancer research content.
Education
Areas of Expertise
Got a Question for Sarah Whelan, PhD?
Get in touch using the contact form linked here and we’ll get back to you shortly.
Published Content
Total: 304
News
Obesity and Diabetes Drugs Could Help To Protect the Kidneys
New research from The George Institute of Global Health shows that a popular class of obesity and type 2 diabetes drugs can reduce a person’s risk of kidney deterioration and failure regardless of whether they have type 2 diabetes or not.
Industry Insight
How Diverse Mouse Models Can Drive Drug Discovery Innovation
We spoke to Prof. Nadia Rosenthal, to find out more about their new approach and how using genetically diverse mice that better reflect human diversity can help find better therapies for a variety of diseases.
News
Short-Term Menopausal Hormone Therapy Has No Lasting Cognitive Effects
Short-term menopausal hormone therapy (mHT) does not have long-term cognitive effects when given to women in early postmenopause, according to new research from Mayo Clinic scientists.
News
Beta-Blockers Linked to Depression for Some Heart Attack Patients
Commonly prescribed beta-blockers may increase the risk of depression for some patients who have had heart attacks, but also have a normal heart pumping ability, new research from Uppsala University suggests.
Industry Insight
How Can We Design Clinical Trials for Older People? We Asked an Expert
At ELRIG Drug Discovery 2024, Technology Networks sat down with Miles Witham, professor of trials for older people at Newcastle University, to learn more about these challenges and how novel approaches can be used to improve current research.
News
Glaucoma Drug Reduces Tau Buildup in Neurodegeneration Model
A common drug used to treat glaucoma has shown promise for neurodegenerative disease, preventing buildup of abnormal tau protein – implicated in dementia – in the brains of zebrafish and mice.
Industry Insight
AI and Bioengineering: How Biotech Start-Ups Are Driving Innovations in Drug Discovery
We reached out to start-ups at ELRIG Drug Discovery 2024 to see how AI and bioengineering can be applied in biotech and drug discovery.
News
Long-Theorized Waste-Clearing Pathway Uncovered in the Human Brain
The glymphatic system, a long-theorized waste-clearing pathway in the brain, has been revealed for the first time in humans, in a new study by Oregon Health and Science University (OSHU) researchers.
News
Sensory Prediction Under Anesthesia May Offer Clues About Conscious Cognition
A new study has examined how the brain constantly works to make predictions about what's happening in our surroundings during consciousness, and how this process breaks down under general anesthesia.
News
Brain Shrinkage Does Not Follow a Pattern in Alzheimer's
Brain shrinkage in people who develop Alzheimer’s disease follows no specific or uniform pattern, according to a new study from University College London (UCL) and Radboud University.
Advertisement
